MOUNTAIN VIEW, Calif.,
May 1, 2012 /PRNewswire/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the
Company will participate in the following investor conferences in
May 2012:
Deutsche Bank 37th Annual Healthcare Conference
Tuesday, May 8, at 8:40 a.m. ET in Boston
Bank of America Merrill Lynch 2012 Healthcare Conference
Tuesday, May 15, at 3:40 p.m. PT in Las
Vegas
A live webcast of each event will be available on the Investor
Relations section of MAP Pharmaceuticals' website at
http://www.mappharma.com. A replay also will be available within 24
hours for seven days following each presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on
developing and commercializing new therapies to address undermet
patient needs in neurology. The Company is developing LEVADEX®, an
orally inhaled investigational drug for the potential acute
treatment of migraine. The U.S. Food and Drug Administration
reviewed the New Drug Application for LEVADEX and on March 26, 2012, the Company received a Complete
Response letter. MAP Pharmaceuticals has entered into a
collaboration agreement with Allergan, Inc. to co-promote LEVADEX
to neurologists and pain specialists in the U.S. and Canada. The Company also applies its
proprietary drug particle and inhalation technologies to generate
new pipeline opportunities by enhancing the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on their known
safety, efficacy and commercialization history. Additional
information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
lborland@mappharma.com
SOURCE MAP Pharmaceuticals, Inc.